Welcome to our dedicated page for Inhibikase Therapeutics SEC filings (Ticker: IKT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Inhibikase Therapeutics, Inc. (Nasdaq: IKT) SEC filings page on Stock Titan provides access to the company’s publicly filed regulatory documents, including current reports on Form 8-K and other submissions made through the U.S. Securities and Exchange Commission’s EDGAR system. As a clinical-stage pharmaceutical company developing Abelson Tyrosine Kinase inhibitor therapeutics for cardiopulmonary disease, Inhibikase uses these filings to report material corporate events, financing transactions, governance matters, and key developments in its pulmonary arterial hypertension (PAH) program.
Inhibikase’s recent 8-K filings describe, among other items, the entry into an underwriting agreement for a public offering of common stock and pre-funded warrants, the expected net proceeds from that offering, and amendments to outstanding warrants in connection with plans to advance IKT-001 to a global pivotal Phase 3 study in PAH. Other 8-Ks report financial results for specific periods, updates to corporate presentations, and outcomes of the company’s annual meeting of stockholders, including director elections, auditor ratification, and equity incentive plan amendments.
Through this page, users can review how Inhibikase discloses its clinical development strategy for IKT-001, including the planned two-part adaptive Phase 3 IMPROVE-PAH study, as well as its capital-raising activities that support ongoing research and development. Stock Titan enhances these filings with AI-powered summaries that explain the core points of lengthy documents such as current reports, shelf registration statements, and related exhibits. Investors can also monitor information related to equity offerings, warrant terms, and other securities matters that may affect the company’s capital structure.
By consolidating Inhibikase’s SEC filings and applying AI-driven analysis, this page helps readers quickly understand the regulatory and financial context surrounding the company’s PAH-focused clinical programs and broader corporate activities.
Form 4 filing – Inhibikase Therapeutics, Inc. (IKT)
On 06/30/2025, director Dennis N. Berman received 108,176 stock options with an exercise price of $1.95 per share. The grant vests on the earlier of 06/30/2026 or the day prior to the company’s next annual shareholder meeting, subject to continued board service, and expires on 06/30/2032. No common shares were bought or sold in this filing; the reporting person’s beneficial ownership now includes the newly issued options, held directly.